SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong
Retrieved on:
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government
The vaccination schedule for this age group follows the same vaccination schedule of older children.
Key Points:
- The vaccination schedule for this age group follows the same vaccination schedule of older children.
- SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
- Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
- SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.